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InheritanceMitochondrial DNA mutations cause disease in N1 in 5000 of the population, and ∼1 in 200 of the population
are asymptomatic carriers of a pathogenic mtDNA mutation. Many patients with these pathogenic mtDNA
mutations present with a progressive, disabling neurological syndrome that leads to major disability and
premature death. There is currently no effective treatment for mitochondrial disorders, placing great
emphasis on preventing the transmission of these diseases. An empiric approach can be used to guide genetic
counseling for common mtDNA mutations, but many families transmit rare or unique molecular defects.
There is therefore a pressing need to develop techniques to prevent transmission based on a solid
understanding of the biological mechanisms. Several recent studies have cast new light on the genetics and
cell biology of mtDNA inheritance, but these studies have also raised new controversies. Here we compare
and contrast these findings and discuss their relevance for the transmission of human mtDNA diseases.© 2009 Elsevier B.V. All rights reserved.1. IntroductionRecent epidemiological studies confirm that pathogenic mitochon-
drial DNA (mtDNA) mutations are a major cause of human disease,
affecting at least 1 in 5000 of the population [1,2]. Pathogenic alleles
are present in N1 in 200 live births [3], and occur de novo at least every
1000 births [3]. Many mtDNA mutations are transmitted down the
maternal line and cause progressive, disabling multi-system disease,
often with devastating effects on the nervous system. Treatment
options are limited [4], and focus on the management of complica-
tions [5]. These facts place great emphasis on the development of
techniques to prevent transmission in the future. This review will
focus on recent advances in our understanding of the biological basis
of mtDNA transmission, highlighting the importance of this work for
human pedigrees transmitting pathogenic mtDNA mutations. The
major focus of this review is on the underlying basic scientific
principles, so we will not discuss clinical techniques under develop-
ment to prevent transmission through nuclear transfer, nor methods
being used for implantation and pre-natal diagnosis (for a considera-
tion of these topics, the reader is referred to several recent reviews
[6–8]). This article also assumes a basic understanding of mtDNA
mutations and human disease which can be obtained from other
articles in this Special Issue of Biochemica et Biophysica Acta on Mito-
chondrial Diseases.Group, The Medical School,
UK. Tel.: +44 191 222 8334;
y).
ll rights reserved.2. Are all pathogenic mtDNA mutations maternally inherited?
MtDNA is almost exclusively maternally inherited in mammals
[9], probably because sperm mtDNA is tagged with ubiquitin and
actively degraded in the early pre-implantation embryo [10]. A
single case of paternal transmission of a pathogenic mtDNA
mutation has been described in a patient with a myopathy [11],
but has not been noted in any other cases despite systematic
investigation [12,13]. Paternal transmission of mtDNA is therefore
likely to be an extremely rare event in humans. In practical terms,
this means that men with mtDNA disease cannot pass the disorder
on to their offspring.
On the other hand, women harbouring homoplasmic mtDNA
mutations can transmit mutated mtDNA to their children. Homo-
plasmic mutations are typically associated with a mild biochemical
phenotype, and cause organ-specific mitochondrial disease. For
example, the three point mutations (11778GNA, 14484TNC;
3460GNA) in complex I (MTND) genes that cause Leber hereditary
optic neuropathy (LHON) preferentially target the retinal ganglion cell
and cause blindness [14]; and the 1555ANG mtDNA 12S rRNA gene
mutation causes isolated sensori-neural deafness [15]. Intriguingly, in
both cases the phenotypic segregation pattern implicates additional
factors in the pathophysiology, including environmental triggers and
interacting nuclear genetic loci [16–18]. However, in both cases it is
possible to determine recurrence risks empirically by observing many
pedigrees [19–21]. With the exception of these two examples,
homoplasmic pathogenic mtDNA mutations have probably been
under-recognised in the past, partly due to difficulties in proving
that a genetic variant is pathogenic and not simply a population
polymorphism [22,23].
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mic, with affected individuals harbouring varying proportions of
mutated and wild-type mtDNA [24]. Given that overall mutation
load broadly correlates with the clinical phenotype [25,26], the
difference in the inherited mutation load partially explains the
clinical variation between siblings in the same family [26–28].
Understanding the mechanism of inheritance of heteroplasmic
mtDNA mutations is a major challenge facing clinicians and
scientists working in the field.
For some pathogenic heteroplasmicmtDNAmutations, the empiric
recurrence risks are low. This led to the previously widely held view
that mtDNA deletions were not transmitted from affected women to
their offspring. Although disease recurrence was observed in some
families, it was thought that related mtDNA duplications were the
actual transmitted molecule, leading to deletion formation in the
offspring [29,30]. However, the detection of an identical deletion in
one mother and child [31] strongly suggests that the deletions
themselves can be transmitted, albeit rarely. A systematic investiga-
tion of over 200 pedigrees estimated the recurrence risk at ∼1 in 24
[32]. There are also a number of rare muscle-specific mtDNA point
mutations which also do not appear to be transmitted [33–36].
Although these apparently sporadic cases could all be due to somatic
mutations that do not involve the germ line, an alternative view is that
these mutations are at one extreme of a spectrum, where there is
selection against the transmission of mutated mtDNA. Understanding
the mechanisms involved provides the key to future prevention
strategies.
3. Heteroplasmic pathogenic mtDNA mutations in human
pedigrees
Women harbouring heteroplasmic mtDNA mutation can transmit
a wide range of heteroplasmy levels to different offspring within the
same sibship. In one meta-analysis of 338 transmitted point muta-
tions, for some mutations the percentage level of mutant mtDNA
tended to increase with transmission, and for others the level seemed
to decrease [37]. However, these data were collected retrospectively
through an affected individual, and the apparent differences could be
due to ascertainment bias [37]. Recent work suggests there may be
selection against 3243ANG during transmission, and that shifts in
heteroplasmy might depend on the level in the mother [38]. Again,
these findings are difficult to interpret because the level of hetero-
plasmy is often markedly different between different tissues and
organs, and the 3243ANG mutation level in blood decreases
exponentially throughout life [39–41]. For some mutations, the level
of heteroplasmy measured in blood is therefore unlikely to reflect the
level in the ovary. On the other hand, for some mtDNA mutations (e.g.
8993TNG/C), the level of heteroplasmy is remarkably consistent in
different tissues, and does not change during life [42]. Under these
circumstances, it may be possible to reliably study transmission by
measuring heteroplasmy values in blood from different family
members [26].
Intriguingly, the change in heteroplasmy seen during transmis-
sion does appear to differ between mutations. Rapid shifts are
commonplace in families transmitting 8993TNG/C [26], but less
likely in families transmitting 8344ANG [43]. This explains why
8993TNG/C pedigrees tend to be small, because the deleterious
mutation is either lost from the maternal line, or reaches very high
levels and causes severe disease in childhood, thus preventing
further transmission [26]. On the other hand, 8344ANG pedigrees are
often large, and span many generations [43]. This anecdotal evidence
implies differences in the mode of transmission between different
genetic variants of mtDNA. Further advances in our understanding of
the mechanisms involved have been revealed by studying the
transmission of ostensibly neutral mtDNA heteroplasmy in other
mammalian species.4. Inheritance of mtDNA heteroplasmy and the genetic bottleneck
By studying the heteroplasmy levels of neutral mtDNA sequence
variants in the blood of a female founder Holstein cow and her
offspring, Hauswirth and Laipis showed that the allele frequency of
these variants rapidly shifted and became fixed in a few generations
[44]. These results led to the proposal of the mitochondrial genetic
bottleneck hypothesis whereby a decrease in the number of
mitochondrial genomes repopulating the offspring of the next
generation causes a sampling effect during transmission, leading to
the rapid changes in heteroplasmy during one generation. The
presence of a mitochondrial genetic bottleneck gained support from
studies of heteroplasmic mice transmitting neutral mtDNA poly-
morphisms. By studying the progeny of mice carrying apparently
neutral BALB/c and NZB mtDNA sequence variants, Jenuth et al.
found that the offspring of a single heteroplasmic mother can have
differing levels of heteroplasmy [45]. The mean level of heteroplasmy
amongst all of the offspring was approximately equal to the
heteroplasmy level seen in the mother, implicating mechanism
governed by random genetic drift [45]. A recent analysis (cite) of
this and other human and animal model data confirms that the
heteroplasmy levels measured in large numbers of cells follow a
distribution from theoretical population genetics based on random
genetic drift [48].
Primordial germ cells (PGCs) are the first committed germ-line
precursor cells in mammals, which usually appear around day 7.25
post conception in the mouse, and day 20 in the human, at the base of
the allantois. By measuring the proportion of BALB/c and NZB mtDNA
sequence variants in mature oocytes, primary oocytes and PGCs,
Jenuth et al. also found that nearly all of the genotypic variance was
generated during the development of the female germ line, and before
the primary oocyte population had been formed. They concluded,
therefore, that the mtDNA bottleneck is occurring at the very early
stages of oogenesis and that for these neutral sequence variants at
least, the transmission of heteroplasmy to the offspring is largely
governed by random genetic drift. The authors estimated the number
of segregating units (i.e. the size of the mouse mtDNA bottleneck)
using an adaptation of the population genetic model of Sewell-Wright
[46], assuming that the genetic bottleneck was fixed over 15 cell
divisions. They predicted a germ-line bottleneck of 185 mtDNA
molecules in the mouse was sufficient to explain the segregation of
BALB/NZB mtDNA heteroplasmy [45].
Evidence that the same mechanism operates in humans transmit-
ting pathogenic mtDNA mutations came from the study of 82 single
primary oocytes from a woman carrying the 3243ANG mtDNA
mutation [47]. The frequency distribution of oocyte mutation load
corresponded to a binomial distribution (although recent analysis
suggests a slightly different distribution provides a more accurate
description [48]). Equal numbers of oocytes had mutation levels
greater or less than the mean, in keeping with the random genetic
drift mechanism, and with the same population genetics model [46]
(adapted for humans, with 23 cell divisions), the bottleneck was
estimated as 173 segregating units [45,47].
5. Drift or selection?
Recent evidence has cast light on this key issue. Stewart et al.
studied the transmission of mtDNA mutations introduced into the
mtDNA mutator mice due to the expression of a proofreading
deficient mtDNA polymerase [49]. Female offspring of these mutator
mice, which carried approximately 30 mutations randomly distrib-
uted throughout the mitochondrial genome, were continuously
backcrossed to wild-type males to remove the mutant POLG gene
but allow the transmission of the heteroplasmic mtDNA mutations
[50]. These heteroplasmic mtDNA mutations were then followed
through 6 successive generations. Results from this study show that
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mutations in the protein coding genes as early as the second
generation when compared to synonymous (silent) changes. This
suggests strong purifying selection against deleterious mtDNA
mutations in the mouse germ line. Interestingly the authors also
noted an excess of mutations in some genes (MTCYB, MTATP6,
MTATP8), which is consistent with findings in humans where there
appear to be a large number of de novo mutations especially in the
ATP6 gene.
Using a different experimental strategy, Fan et al. also found
evidence for purifying selection by studying the transmission of a
MTND6 frameshift mutation which inactivates oxidative phosphor-
ylation complex I when homoplasmic [51]. The MTND6 mutation was
eliminated from the mouse female germ line within four generations.
In contrast, a milder mis-sense mutation in the cytochrome c oxidase
subunit I gene (MTCOI), which reduced complex IV activity by 50%
when homoplasmic, was repeatedly transmitted over successive
generations despite causing mitochondrial myopathy and a cardiac
phenotype [51]. Taken together with the study from Stewart et al.
these results provide evidence for selection of some mtDNA
mutations in the mouse female germ line and suggest that these
severe mtDNA mutations encoding non-synonymous changes are
selected against at the organelle level. However, the mechanism may
not be straight-forward, with some deleterious mutations being
selected against (purifying selection), and some possibly undergoing
positive section [24].
6. How is mtDNA inherited?
Recent technological advances have enabled three groups to
directly test the bottleneck hypothesis by measuring mtDNA in
single cells during early development [52–54]. Stella is one of the
first proteins expressed by the committed germ line [55]. By
studying pre-implantation mouse embryos and Stella-GFP transgenic
mice to unambiguously identify PGCs using quantitative PCR, we
showed that the amount of mtDNA within individual PGCs has a
median value of 203 molecules at 7.5 days post conception (dpc)
[53]. These first discernable PGCs contained substantially lower
mtDNA copy numbers than that of the individual blastomeres
making up pre-implantation embryos. Following implantation, we
showed that the mtDNA copy number in the PGCs steadily increased
as the cells migrate to the genital ridge, reaching ∼1500 copies in
each PGC by 14.5 dpc, however this is still almost 100 fold lower
than the level seen in the mature oocyte. Using this experimental
data to model the segregation and replication of mtDNA between
dividing cell in the germ line, we showed that the mtDNA copy
numbers that we measured could cause a genetic bottleneck which
explains the genotypic variance seen in the offspring of 246
offspring from 22 litters born to mothers with different levels of
NZB/C57Bl.6J heteroplasmy. This work study suggests ∼70% of the
heteroplasmy variance is generated due to the unequal portioning of
mtDNA molecules into daughter cells during both pre- and post-
implantation development, when the amount of mtDNA molecules
within the cell drops to a median value of approximately 200. The
remaining ∼30% variance being generated during the mitotic
expansion of the PGC population, where copy number values
approximate 1500 molecules [53]. However, direct measurements
of heteroplasmy were not made at each stage in development in
these experiments.
In an earlier study, Cao et al. also estimatedmtDNA copy number in
mature oocytes, pre-implantation embryos and PGCs [52]. Whilst
copy number values in mature oocytes and pre-implantation embryos
were similar to both our own data and those of others [53,56], the
average value in day 7.5 PGCs was ∼1700 copies, which was
significantly higher than the 200 copies we measured at the same
time point. Intriguingly, Cao et al. did not report any difference in themtDNA copy number between 7.5 dpc and 13.5 dpc and concluded
that the mtDNA bottleneck was not due to a decrease in mtDNA copy
number in early oogenesis, rather that it is due to a small effective
number of segregating units, each containing several mtDNA
molecules [52]. Differences in methodologies may explain these
apparent inconsistencies. Cao et al. used alkaline phosphatase
histochemistry to identify the primordial germ cells in contrast to
the Stella-GFP transgenic mouse used in our study. In our hands real-
time PCR traces strongly suggested that the alkaline phosphatase
stained cells inhibited the real-time PCR reaction in a stochastic
manner, increasing the variability between measurements and
potentially compromising the result.
It is also possible that the two studies focused on slightly
different developmental stages. At any given time there is
considerable variation in the developmental stage of individual
mouse embryos [57]. This is partly due to subtle variations in the
precise time of conception, which cannot be directly controlled. For
example, at 7.5 dpc, embryos range between the mid-streak stage
and the early head-fold stage even within the same litter [57]. PGCs
appear from the early allantoic bud neural plate stage. Cao et al.
identified and studied late allantoic bud stage embryos. By contrast,
using flow cytometry and a highly-specific PGC marker, we studied
both early and late allantoic bud stage embryos [53]. In keeping
with this, the range of mtDNA copy number values at 7.5 dpc
reported by Cao et al. (1258 to 3335) fell within the upper end of
the range of values we reported (26 to 3402) [53]. The lower copy
numbers that we measured could therefore have been from early
allantoic bud stage embryos, which Cao et al. specifically did not
study. This suggests that the early allantoic bud stage is the time
point when the amount of mtDNA within individual PGCs falls to its
lowest level.
Using a different approach, Wai et al. have recently challenged the
currently held notion that the genetic bottleneck occurs during
embryonic oogenesis [54]. Using heteroplasmic mice expressing
EGFP from a modified Oct4 promoter they measured both mtDNA
copy number and genotypic variance in both the post-implantation
and post-natal stages of female development. During embryonic
oogenesis, the primordial germ cells contained ∼280 copies of
mtDNA at 8.5 dpc, rising to ∼2200 copies by 10.5 dpc. These results
are consistent with those of Cree et al. (but not Cao et al. [52]),
confirming that our direct measurement of the bottleneck was
accurate [53]. By 14.5 dpc this had risen to ∼6000 copies of mtDNA
per cell. These results suggest that there is still a far lower mtDNA
copy number within the developing PGCs compared to fertilized
oocytes (700 fold lower at 8.5 dpc, rising to 10–20 fold at 14.5 dpc).
Using two nonparametric tests for equal variances, Wai et al. [54] did
not observe a corresponding increase in genotypic variance over this
same time point. However, when they studied post-natal develop-
ment they noted a disparity in the genotypic variance between PGCs,
oogonia and primary oocytes when compared to mature ovulated
oocytes and primary oocytes within secondary follicles, implicating
the post-natal expansion of mtDNA in the generation of varying
heteroplasmy levels. Moreover, the authors used BrdU to label
replicating mtDNA and staining using TFAM, mt-SSB and POLG, all
markers of the mammalian nucleoid. They noted that only a
subgroup of nucleoids was replicating in the primordial and primary
follicles. They therefore suggested that this provides further evidence
for selection of a random subset of nucleoids for replication in these
cells (Fig. 1).
In conclusion, two independent studies agree that there is a
significant reduction in mtDNA content within early PGCs, to a value
of ∼200 copies per cell. The data of Wai et al. [54] directly implicates
a post-natal mechanism in generating some of the increased
variance between oocytes, but the absence of statistically significant
increased variance between PGCs before birth does not mean that
variation is not being generated at this time point. The only firm
Fig. 1.Models of the mitochondrial genetic bottleneck adapted from [52]. Schematic diagram showing a heteroplasmic fertilized oocyte (top), a model of the mitochondrial genetic
bottleneck (middle) and subsequent oocytes (bottom). Blue circles=wild-type mtDNA. Red circles=mutated mtDNA. (a) Prenatal bottleneck. The variance in heteroplasmy levels
arises during early embryo and germ-line development due to the random segregation of individual mtDNA molecules before the primary oocyte stage. This model is based on the
actual amount of mtDNA measured within single cells as reported in [52] and [53]. Time scale shown on the left in days post coitus (dpc). (b) Postnatal bottleneck. The variance in
heteroplasmy levels arises after birth due to the preferential replication of a subpopulation of mtDNA molecules as proposed in [53].
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variance did not change sufficiently to reject the null hypothesis of
no variance on which the statistical tests were based. In other words,
the results could simply reflect differences which fell below thedetection threshold for statistical tests used to compare limited data
sets. Direct measurements of heteroplasmy in large numbers of PGCs
and oocytes at each stage of development are required to resolve
this issue.
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The molecular and cellular mechanisms of inheritance of mtDNA
have been a source of intense speculation for decades, but recent
technical advances have started to resolve some of the key issues in
mice. It is now clear that selection operates during the transmission of
some heteroplasmy mtDNA mutations in mice, but the mechanisms
may lead to either the loss or accumulation of pathogenic mtDNA
mutations. Although there does appear to be a restriction in mtDNA
content early in the mouse germ cell lineage, direct experimental
evidence is required to prove that this “bottleneck”makes a substantial
contribution to the variation in heteroplasmy levels seen amongst the
offspring of heteroplasmic female mice. The relative contribution of
pre- and post-natal oocyte development in generating variation on
heteroplasmy levels has yet to be established, and several major
questions still remain. What genes control the genetic bottleneck? Is
the bottleneck the same for all mtDNAmutations? How variable is the
bottleneck between individuals? Does the samemechanism operate in
humans? Can we manipulate the mechanism to prevent the
transmission of pathogenic mtDNA mutations? The answers to these
questions are just around the corner, providing hope for families
transmitting these common but devastating genetic diseases.
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